44P Dostarlimab (dos) or Pembrolizumab (pem) + Chemotherapy (CT) in Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Patient (pt) and Disease Characteristics Subgroup Analyses from the PERLA Trial

The randomized, double-blind phase II PERLA trial was the first global head-to-head comparison of 2 programmed death (PD)-1 inhibitors in NSCLC and showed similar efficacy for Dos + CT and Pem + CT with no new safety signals identified. Here, we report overall response rate (ORR) by pt and disease characteristics.